According to the most recent SEC filing, the fund increased its holdings of the company's stock by 5.5% during the fourth quarter. The fund now owns 3,517,125 of the stock of the company after adding 183,971 additional shares over the past quarter. GH Research is the 6th most valuable stock in VR Adviser LLC portfolio. It comprises approximately 5.5%. VR Adviser LLC held 0.07% in GH Research, worth $34,186,000 at the time of its latest filing with SEC.
GHRS has also been the subject of changes by other hedge funds. Bank of America Corp DE increased its holdings of shares of GH Research from 13,760.0% to $27,000 during the fourth quarter. Bank of America Corp DE owns now 2,772 of the company’s stock worth $27,000, after buying an additional 2,752 during the last quarter. Tower Research Capital LLC TRC increased its stake in GH Research from 277.1% to $39,000 during the third quarter. Tower Research Capital LLC TRC owns 3,383 of the company’s stock worth $39,000, after purchasing 2,486 additional shares during the last quarter. Exchange Traded Concepts LLC increased the position it held in shares of GH Research in the fourth quarter by 126.8%. Exchange Traded Concepts LLC owns 11,510 of the company stock, worth $111,000, after purchasing 6,435 additional shares during the last quarter. State Street Corp purchased a new stake of approximately $127,000 in shares of GH Research. Cornerstone Investment Partners LLC also purchased a stake in GH Research during the fourth quarter, valued at about $144,000. During Monday's midday trading, the stock rose $0.11 to $12.35. 13 507 shares were traded, compared with its average volume which is 65,198. The fifty-day simple moving is $9.79, and the two hundred day simple is $9.65. GH Research PLC's 52-week low is $5.70, and its 52-week highest is $17.41. The market capitalization is $618.38 millions, with a PE of -23.30.
The company announced its last quarterly earnings report on Thursday, 11th May. The company posted ($0.21) in earnings per share for the quarter. This beat the consensus estimate ($0.24) by $0.03. Analysts expect GH Research PLC to post -1.07 EPS in the current year.
Wall Street analysts weigh in
Recently, a number of analysts published reports about the company. EF Hutton Acquisition Co. In a report published on Thursday, 2nd March, I reiterated my 'buy rating' and set a target price of $33.00 for shares of GH Research. JMP Securities increased their price target on GH Research in a report published on Friday, May 12. In a report published on Monday, March 13, HC Wainwright reiterated a buy' rating on GH Research and set a target price of $45.00.
About GH Research
The company's leading program is GH001, a mebufotenin inhalable product candidate which has completed two Phase I clinical trials and a Phase 1/2 clinical study in patients with TRD.
MarketBeat.com offers a FREE daily email newsletter